Environmental impact assessment for the 750-tonne project has entered public consultation stage in Hebi Baoshan Economic and Technological Development Zone
Chinese agrochemical manufacturer Hebi Quanfeng Biotech has moved to strengthen its position in the plant growth regulator segment with plans to establish a new annual 750-tonne production facility focused on key active ingredients including prohexadione calcium, trinexapac-ethyl, and uniconazole. The proposal has now entered the public consultation stage following the release of the project’s environmental impact assessment documentation.
The planned technical renovation project will be located within the Hebi Baoshan Economic and Technological Development Zone and is designed to significantly enhance the company’s production capabilities in the high-value plant growth regulator category. According to the disclosed plans, the facility will include annual production capacities of 250 tonnes of prohexadione calcium, 50 tonnes of trinexapac-ethyl, and 400 tonnes of uniconazole.
The expansion reflects the growing strategic importance of plant growth regulators in modern agriculture, particularly amid rising demand for crop management solutions aimed at improving yield efficiency, stress tolerance, and crop uniformity. Products such as prohexadione calcium and uniconazole are widely used to regulate plant growth, optimise crop architecture, and improve resistance to lodging and environmental stress in commercial agriculture systems.
Founded in October 2016, Hebi Quanfeng Biotech has established itself as a specialised player in the research, development, production, and marketing of plant growth regulators. The company is regarded as one of China’s significant producers of plant growth regulator technical materials and has developed integrated synthesis capabilities across a broad portfolio of active ingredients.
Its existing product range includes prohexadione calcium, chlormequat chloride, paclobutrazol, naphthylacetic acid, diethyl aminoethyl hexanoate, ethephon, uniconazole, benzyl aminopurine, forchlorfenuron, trinexapac-ethyl, and diflubenzuron. The proposed facility is expected to deepen the company’s manufacturing scale and reinforce its positioning within China’s increasingly competitive agrochemical industry.
The project also reflects a broader trend within the global crop protection and plant physiology market, where demand is steadily shifting toward precision-oriented agricultural inputs capable of improving productivity while optimising resource efficiency. As agricultural systems worldwide confront climate variability, labour constraints, and pressure for higher productivity, plant growth regulators are emerging as an increasingly important component of integrated crop management strategies.
With the latest expansion initiative, Hebi Quanfeng Biotech appears to be positioning itself to capture a larger share of this evolving market, leveraging both technical synthesis expertise and scale expansion to strengthen its long-term competitiveness in the specialty agrochemical segment.
